Allotera Therapeutics
PrivateLast Round
Series C
Extension
Jul 8, 2026
Total Funding Raised
$394M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Allotera Therapeutics is a biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for the treatment of hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allotera Therapeutics Comparables
Compare Allotera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bioheng Therapeutics | 89% | |
| Beam Therapeutics | 83% | |
| AvenCell | 81% |
Allotera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jul 8, 2026 | ||||
| Series C | Aug 27, 2025 | ||||
| Series B | Jul 15, 2021 | ||||
| Series A | Apr 13, 2020 |
Key People
Founding team and executive leadership
Allotera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LYZZ Capital | Series B, Series C, Series A |
| Intermediate Capital Group | Series C, Series B |
| Fidelity Management & Research Company | Series B, Series C |
| BioGenerator Ventures | Series C Extension, Series A |
| Tybourne Capital Management | Series C, Series B |
| RiverVest Venture Partners | Series B, Series C, Series A |
| Abingworth | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 8, 2026
$35M round with participation from BioGenerator Ventures and LightChain Capital.
- Aug 27, 2025
$115M raised in early funding.
Allotera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Allotera Therapeutics's valuation, stock price, and market status.
Is Allotera Therapeutics a public or private company?
Allotera Therapeutics is a private company.
What is the current stock price of Allotera Therapeutics?
Allotera Therapeutics is a private company, so its shares have no public market price. Caplight tracks Allotera Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allotera Therapeutics worth (valuation)?
Valuation information for Allotera Therapeutics is not publicly available.
Can I buy Allotera Therapeutics stock?
Allotera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allotera Therapeutics's last funding round?
Allotera Therapeutics's most recent funding round was Series C Extension on July 8, 2026.
Who are the main investors in Allotera Therapeutics?
Key investors in Allotera Therapeutics include Fidelity Management & Research Company, Tybourne Capital Management, RiverVest Venture Partners, Abingworth.
Will Allotera Therapeutics IPO soon?
No public IPO plans have been announced for Allotera Therapeutics.
How can I track Allotera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Allotera Therapeutics's shares on secondary markets.